Skip to content
Medical Health Aged Care

KFSHRC Launches the First Facility for Gene and Cell Therapy Manufacturing in Saudi Arabia

King Faisal Specialist Hospital & Research Centre 3 mins read

RIYADH, Saudi Arabia, Oct. 27, 2025 (GLOBE NEWSWIRE) -- King Faisal Specialist Hospital and Research Centre said it will open Saudi Arabia’s first facility for manufacturing genetic and cellular therapies by late 2025, a project designed to give thousands of patients access to advanced treatments at home, reduce the cost of care by an estimated eight billion riyals — about two billion dollars — by 2030, and meet roughly nine percent of the nation’s demand for such therapies.

The new plant, located on the hospital’s Riyadh campus, will produce CAR T-cell and stem-cell therapies, treatments that re-engineer a patient’s own cells to fight cancer or repair damaged tissue. Spanning more than 5,000 square meters, the facility is designed around 16 modular clean-room clusters that can expand or adapt as new therapeutic technologies evolve.

Officials said the complex marks a milestone in Saudi Arabia’s biotechnology ambitions, bringing precision medicine and advanced manufacturing together. Once fully operational, it is expected to manufacture about 2,400 treatment doses each year, advancing the country’s capacity to produce some of the world’s most sophisticated therapies.

The facility will operate under Good Manufacturing Practice standards, the global framework that governs pharmaceutical production. Each process, from air filtration to batch testing, will be monitored to ensure sterility, safety, and consistency. Artificial-intelligence systems will manage quality control, while the modular layout allows rapid scaling as innovation grows.

KFSHRC already has experience in the field. More than 200 patients have received CAR T-cell therapy there since 2020, years before local manufacturing began. The new site builds on that clinical record while advancing a broader research and training ecosystem aimed at preparing Saudi scientists and attracting global experts in gene and cell therapy. Officials said the goal is to make the kingdom not only a center for treatment but also for drug discovery and manufacturing.

At this year’s Global Health Exhibition 2025 in Riyadh, the hospital is showcasing the new manufacturing complex alongside its advances in robotic surgery, genetic diagnostics, and augmented-reality medical training. The presentation highlights how the country’s flagship hospital is aligning with broader national efforts to shift from healthcare consumption to healthcare creation.

KFSHRC has been ranked first in the Middle East and North Africa and fifteenth globally among the world’s top 250 academic medical centers for 2025. It was also recognized by Brand Finance 2025 as the most valuable healthcare brand in the Middle East and listed in Newsweek’s World’s Best Hospitals 2025, Best Smart Hospitals 2026, and Best Specialized Hospitals 2026, reaffirming its position as a global leader in innovation-driven patient care.

For more information, visit www.kfshrc.edu.sa or contact our media team at [email protected]

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/c9ee13e5-9172-4352-8980-34db6df55b50


Primary Logo

More from this category

  • Medical Health Aged Care
  • 15/08/2026
  • 07:02
Optimi Health Corp.

Optimi Health Establishes Discretionary Equity Facility

VANCOUVER, British Columbia, Aug. 14, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (NASDAQ: OPTH) (CSE: OPTI) (FSE: 8BN) (the “Company” or “Optimi”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it has entered into a common shares purchase agreement (the “Purchase Agreement”) with Seven Knots, LLC (“Seven Knots”), establishing an equity line of credit (the “ELOC”) under which the Company has the right, but not the obligation, to sell to Seven Knots up to US$100 million of its common shares from time to time over the term of the facility.Sales under the ELOC are at the…

  • Medical Health Aged Care, Research Development
  • 14/08/2026
  • 08:00
Australia New Zealand Gynaecological Oncology Group (ANZGOG)

ANZGOG opens 2026 Fund for New Research Grants to accelerate the next generation of gynaecological cancer research

MEDIA RELEASE Friday, 14 August 2026 ANZGOG opens 2026 Fund for New Research Grants to accelerate the next generation of gynaecological cancer research The Australia New Zealand Gynaecological Oncology Group (ANZGOG) has today opened applications for its 2026 Fund for New Research Grant Program, supporting researchers to investigate promising ideas and generate the evidence needed to progress larger studies and future clinical trials. Supported by significant contributions from ANZGOG donors, the 2026 program will fund four priority research areas, with grants ranging from $50,000 to $100,000: Endometrial cancer focused surgical study – one grant of up to $55,000 Leiomyosarcoma focused…

  • Animal Animal WelfareRights, Medical Health Aged Care
  • 13/08/2026
  • 10:30
Monash University

Monash experts: Avian Influenza

Monash University experts are available to discuss the spread of H5 bird flu and its implications across native bird populations, agriculture, farming and general preparedness. Professor Anne Peters, specialist in the behaviour ecology and conservation of birds, Deputy Head of School of Biological Sciences,Monash University Contact details: +61 3 9903 4840 or [email protected] Read more Analysis and Opinion from Professor Peters The following can be attributed to Professor Peters: “Regarding theflu being detected in silver gulls, this is obviously very concerning. These seagulls are what many people know as the 'fish & chip' gull, i.e. they are common, range widely,…

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.